FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324414936> ?p ?o ?g. }

• W2324414936 endingPage "S225" @default.
• W2324414936 startingPage "S224" @default.
• W2324414936 abstract "Fludarabine is a common constituent of conditioning for hematopoietic cell transplantation (HCT). It is a prodrug that is dephosphorylated in plasma to its measurable metabolite, F-ara-A, which after intracellular rephosphorylation interferes with DNA replication, transcription and translation, and induces apoptosis. Due to variable renal clearance, F-ara-A levels on day 0 are variable. The clinical relevance of the F-ara-A persisting in plasma is unknown. The goal of this study was to assess the relationship between F-ara-A levels on day 0 and clinical outcomes including GVHD, infections, relapse and death. We included 166 consecutive patients undergoing first allogeneic transplantation of filgrastim-mobilized blood stem cells for a hematologic malignancy between December 2008 and 2012. Conditioning was myeloablative, and included fludarabine (50 mg/m2 daily from days -6 to -2), busulfan and antithymocyte globulin. Additional GVHD prophylaxis included methotrexate and cyclosporine. The interval between the last fludarabine dose and graft infusion was 48-72 hours. F-ara-A serum levels were measured using mass spectrometry. In univariate analyses, there was no difference in median F-ara-A levels between patients who did vs did not develop acute GVHD grade 2-4, acute GVHD grade 3-4, any chronic GVHD, chronic GVHD needing systemic therapy (NST), CMV reactivation above our threshold for preemptive therapy (25,000 IU/mL), post-transplant lymphoproliferative disorder (PTLD), relapse, death or non-relapse death (Figure 1). In multivariate analyses, there was no difference in the likelihood of developing any one of the outcomes between patients whose F-ara-A level was above vs below median (14 ng/mL). We also assessed for differences in the likelihood of developing each outcome between patients with levels in the fourth quartile (21-104 ng/mL) vs the first quartile (1-9 ng/mL). Again, in this analysis, there was no difference for any outcome. We also noted a weak correlation between F-ara-A levels on day 0 and the day of neutrophil engraftment (r=0.16, p=0.04), and a trend towards more bacterial infections in patients with F-ara-A levels in the fourth vs first quartile. The results suggest that there is no or minimal impact of day 0 F-ara-A levels on clinical outcomes. This may be due to the fact that F-ara-A levels on day 0 were relatively low (1-104 ng/mL, median 14 ng/mL) compared to levels 1-4 hours after fludarabine infusion (∼1,000 ng/mL). Day 0 F-ara-A levels are highly variable (1-104 ng/mL), likely due to variable renal function. Given that we found no association between the day 0 levels and clinical outcomes we do not support delaying graft infusion until F-ara-A level has dropped below a certain level, as long as the last fludarabine dose is given within 48 hours of graft infusion and to patients with normal renal function." @default.
• W2324414936 created "2016-06-24" @default.
• W2324414936 creator A5014747990 @default.
• W2324414936 creator A5016527172 @default.
• W2324414936 creator A5017963135 @default.
• W2324414936 creator A5025720984 @default.
• W2324414936 creator A5040996602 @default.
• W2324414936 creator A5048122779 @default.
• W2324414936 creator A5056645942 @default.
• W2324414936 creator A5065982019 @default.
• W2324414936 creator A5070022492 @default.
• W2324414936 creator A5071194831 @default.
• W2324414936 creator A5073498793 @default.
• W2324414936 creator A5084879148 @default.
• W2324414936 date "2014-02-01" @default.
• W2324414936 modified "2023-10-17" @default.
• W2324414936 title "Fludarabine Metabolite Level on Day Zero Does Not Affect Outcomes of Hematopoietic Cell Transplantation in Patients with Normal Renal Function" @default.
• W2324414936 doi "https://doi.org/10.1016/j.bbmt.2013.12.379" @default.
• W2324414936 hasPublicationYear "2014" @default.
• W2324414936 type Work @default.
• W2324414936 sameAs 2324414936 @default.
• W2324414936 citedByCount "0" @default.
• W2324414936 crossrefType "journal-article" @default.
• W2324414936 hasAuthorship W2324414936A5014747990 @default.
• W2324414936 hasAuthorship W2324414936A5016527172 @default.
• W2324414936 hasAuthorship W2324414936A5017963135 @default.
• W2324414936 hasAuthorship W2324414936A5025720984 @default.
• W2324414936 hasAuthorship W2324414936A5040996602 @default.
• W2324414936 hasAuthorship W2324414936A5048122779 @default.
• W2324414936 hasAuthorship W2324414936A5056645942 @default.
• W2324414936 hasAuthorship W2324414936A5065982019 @default.
• W2324414936 hasAuthorship W2324414936A5070022492 @default.
• W2324414936 hasAuthorship W2324414936A5071194831 @default.
• W2324414936 hasAuthorship W2324414936A5073498793 @default.
• W2324414936 hasAuthorship W2324414936A5084879148 @default.
• W2324414936 hasBestOaLocation W23244149361 @default.
• W2324414936 hasConcept C126322002 @default.
• W2324414936 hasConcept C143998085 @default.
• W2324414936 hasConcept C144301174 @default.
• W2324414936 hasConcept C203014093 @default.
• W2324414936 hasConcept C2776694085 @default.
• W2324414936 hasConcept C2776755627 @default.
• W2324414936 hasConcept C2777408962 @default.
• W2324414936 hasConcept C2778684742 @default.
• W2324414936 hasConcept C2779263901 @default.
• W2324414936 hasConcept C2911091166 @default.
• W2324414936 hasConcept C38180746 @default.
• W2324414936 hasConcept C71924100 @default.
• W2324414936 hasConcept C90924648 @default.
• W2324414936 hasConceptScore W2324414936C126322002 @default.
• W2324414936 hasConceptScore W2324414936C143998085 @default.
• W2324414936 hasConceptScore W2324414936C144301174 @default.
• W2324414936 hasConceptScore W2324414936C203014093 @default.
• W2324414936 hasConceptScore W2324414936C2776694085 @default.
• W2324414936 hasConceptScore W2324414936C2776755627 @default.
• W2324414936 hasConceptScore W2324414936C2777408962 @default.
• W2324414936 hasConceptScore W2324414936C2778684742 @default.
• W2324414936 hasConceptScore W2324414936C2779263901 @default.
• W2324414936 hasConceptScore W2324414936C2911091166 @default.
• W2324414936 hasConceptScore W2324414936C38180746 @default.
• W2324414936 hasConceptScore W2324414936C71924100 @default.
• W2324414936 hasConceptScore W2324414936C90924648 @default.
• W2324414936 hasIssue "2" @default.
• W2324414936 hasLocation W23244149361 @default.
• W2324414936 hasOpenAccess W2324414936 @default.
• W2324414936 hasPrimaryLocation W23244149361 @default.
• W2324414936 hasRelatedWork W1977590412 @default.
• W2324414936 hasRelatedWork W2085715737 @default.
• W2324414936 hasRelatedWork W2093184657 @default.
• W2324414936 hasRelatedWork W2111558234 @default.
• W2324414936 hasRelatedWork W2579362930 @default.
• W2324414936 hasRelatedWork W2589650074 @default.
• W2324414936 hasRelatedWork W2609272607 @default.
• W2324414936 hasRelatedWork W2747131114 @default.
• W2324414936 hasRelatedWork W3190263142 @default.
• W2324414936 hasRelatedWork W3205044970 @default.
• W2324414936 hasVolume "20" @default.
• W2324414936 isParatext "false" @default.
• W2324414936 isRetracted "false" @default.
• W2324414936 magId "2324414936" @default.
• W2324414936 workType "article" @default.